应用SELDI质谱技术筛选胰腺癌患者的血清标志蛋白

目的:探讨应用SELDI质谱技术对胰腺癌患者血清中特异性标志蛋白的筛选方法。方法:采用表面增强激光解析/离子化飞行时间质谱（SELDI-TOF-MS）技术，选择WCX磁珠及蛋白芯片阅读机对胰腺癌及健康人(对照组)和胰腺良性疾病组的血清进行检测，以筛选胰腺癌患者血清中特异表达差异蛋白。结果:发现胰腺癌血清表达差异的潜在标志物（蛋白）4个，相对分子质量分别为5 705 Da，4 935 Da,5 318 Da和3243 Da，其中4 935 Da，3 243 Da差异表达蛋白质在对照组中低表达，而在胰腺癌组中高表达，5 705 Da和5 318 Da差异表达蛋白质在胰腺癌组中低表达而对照组中高表达。结论:应用SELDI技术筛选胰腺癌患者血清中的特异性生物标记物的方法快速、有效;检测到的4个差异蛋白质可能是胰腺癌患者血清特异性生物标记物。     

胆囊息肉样病变的诊断和治疗

胆囊息肉样病变(polypoid lesions of gallbladder,PLG)是一类表现为胆囊黏膜向腔内突起的局限性息肉样突起病变的总称.此类疾病包含良、恶性病变20余种[1].     

Diagnosis of tumor-like polypoid lesions of gallbladder by serum proteomic fingerprint

Objective:To search the specific serum proteins in tumor-like polypoid lesions of the gallbladder(PLG)patients. Methods:Surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS)technique and WCX Magnetic Beads were used to detect the serum proteomic fingerprint of 23 patients with tumor-like PLG,21 patients with non tumor-like PLG and 26 normal persons.Biomarker Wizard and Biomarker Patterns Software were used in combination to analyze the data.Results:In the preliminar...     

胰腺囊性肿瘤临床诊断和治疗分析

胰腺囊性肿瘤是一种较少见的肿瘤.约占胰腺肿瘤的1%,极易造成误诊和误治[1].本研究回顾性分析23例胰腺囊性肿瘤患者的临床资料,结果报道如下.     

Serum protein fingerprint of patients with pancreatic cancer by SELDI technology

Objective： To study the serum protein fingerprint of patients with pancreatic cancer and to screen for protein molecules closely related to pancreatic cancer during the onset and progression of the disease using surface-enhanced laser desorption and ionization time of fight mass spectrometry （SELDI-TOF-MS）. Methods： Serum samples from 20 pancreatic cancers, 20 healthy volunteers and 18 patients with other pancreatic diseases. WCX magnetic beans and PBSII-C protein chips reader （Ciphergen Biosystems Ins.） were used. The protein fingerprint expression of all the Serum samples and the resulting profiles between cancer and normal were analyzed with BiomarkerWizard system. Results： Agroup ofproteomic peaks were detected. Four differently expressed potential biomarkers were identified with the relative molecular weights of 5705 Da, 4935 Da, 5318 Da and 3243 Da. Among them, two proteins with m/z5705, 5318Da down-regulated, and two proteins with m/z 4935, 3243 Da were up-regulated in pancreatic cancers. Conclusion： SELDI technology can be used to screen significant proteins of differential expression in the serum of pancreatic cancer patients. These different proteins could be specific biomarkers of the patients with pancreatic cancer in the serum and have the potential value of further investigation.     

腹腔镜联合内镜治疗58例胆囊结石合并胆总管结石

目的 探讨腹腔镜胆囊切除术(LC)前应用内镜oddis扩约肌切开取石术(EST)联合治疗胆囊结石合并胆总管结石的疗效.方法 回顾性分析58例胆囊结石合并胆总管结石应用LC联合EST治疗的临床资料.结果 本组均先行EST取石无严重并发症后2～3 d行LC.58例中55例(94.83%)EST、LC联合治疗成功,无中转开腹及严重并发症.住院时间6～15(7.2±2.4)d.结论 LC术前应用EST联合治疗胆囊结石合并胆总管结石效果安全可靠.     

SELDI-TOF-MS技术在胰腺癌诊断中的应用

目的 应用表面增强激光解析/离子化飞行时间质谱技术(SELDI-TOF-MS)从胰腺癌患者血清中筛选标志蛋白,找出最佳的标志蛋白组合模式作为临床诊断指标.方法 收集29例胰腺癌患者血清标本和57例年龄、性别相匹配的非癌人群血清标本作为对照.采用SELDI技术检测其蛋白质指纹图谱表达,所得到的结果采用Biomarker Wizard及Biomarker Patterns system软件分析,筛选最终可能用于胰腺癌诊断的蛋白标志物并优化组合建立胰腺癌诊断模型.结果 发现胰腺癌患者和对照组血清蛋白质指纹图谱之间有26个差异表达特异性蛋白,分析系统筛选出一组包含4个标志蛋白(5705、4935、5318和3243 Da)建立起一个胰腺癌的诊断模型,对胰腺癌诊断的敏感性为100%,特异性97.4%.盲法验证此模型敏感性88.9%、特异性89.5%.结论 SELDI-TOF-MS技术的特异性及敏感性远远高于目前所采用的某一单独标志物的血清学诊断,其结果对进一步研究胰腺癌的蛋白质组学改变及其临床诊断应用可能具有重要意义.     

早期胃癌的57例临床诊治分析

胃癌是我国常见的消化道恶性肿瘤之一,其预后与确诊时的病理分期密切相关,早期胃癌（early gastric carcinoma,EGC）的预后明显好于中晚期胃癌[1]。然而,我国EGC的检出率较低,原因在于EGC多无症状或缺乏典型的临床表现,普查的依从性差,费用较高,发现时多已处于进展期。